Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 21INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Hyperglycemia 1Hereditary Sensory and Autonomic Neuropathies 1Diabetes Mellitus, Type 2 1Diabetes Mellitus 1Breast Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × dapagliflozin × Clear all
NCT07033585 2025-07-11

GD-T2D

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting
600 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2

NCT04899349 2024-10-09

EPIK-B4

Novartis

Phase 2 Terminated
2 enrolled 8 charts
Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡